A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Clinical Trial ID NCT02087423

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antibodies to watch in 2016.	MAbs	2015	1.17
2	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
3	Clinical impact of checkpoint inhibitors as novel cancer therapies.	Drugs	2014	0.99
4	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
5	Advances in immunotherapy for treatment of lung cancer.	Cancer Biol Med	2015	0.95
6	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.	J Thorac Oncol	2015	0.87
7	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.	Oncologist	2015	0.81
8	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.	Ther Adv Med Oncol	2016	0.81
9	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.	Oncotarget	2016	0.79
10	Recent Advances in Immunotherapy in Metastatic NSCLC.	Front Oncol	2016	0.79
11	Challenges and future perspectives of T cell immunotherapy in cancer.	Immunol Lett	2015	0.78
12	Promising targets and current clinical trials in metastatic squamous cell lung cancer.	Front Oncol	2014	0.78
13	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy.	Onco Targets Ther	2016	0.78
14	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.	Ann Transl Med	2016	0.77